Effects of Tacrolimus and Other Immune Targeting Compounds on Binge-Like Ethanol Drinking in High Drinking in the Dark Mice
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- High Drinking in the Dark (HDID-1) mice, a genetic model of binge-like drinking
- Dose used in the study
- Palmitoylethanolamide 0, 75, 150 or 225 mg/kg; also tacrolimus, sirolimus and secukinumab at several doses; route not stated in the abstract
- Duration
- 2-day Drinking in the Dark test
- What was measured
- Binge-like ethanol intake and blood alcohol levels; water and saccharin intake.
What the authors reported
Tacrolimus reduced ethanol intake and blood alcohol levels, and reduced saccharin but not water intake. Palmitoylethanolamide, sirolimus and secukinumab had no effect on ethanol intake or blood alcohol levels at any dose tested.
Limits of this study
A mouse model; it cannot show effect in people. PEA gave a null result here. The authors declare no conflicts of interest.
Source
PubMed 33294845 · doi:10.1177/2633105520975412
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.